Work

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus

Year: 2017
Type: article
Abstract: rom a clinical perspective, type 2 diabetes mellitus might also be regarded as a vascular disease, characterized by increased arterial stiffness.Empagliflozin is a selective sodium-glucose cotransporter 2 inhibitor shown to improve glycemic control after short-and long-term treatment.1 In the EMPA-REG OUTCOME study (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), a prospective randomized double-blind study in patients with type 2 diabetes mellitus with established cardiovascular disease, treatment with empagliflozin reduced the primary combined cardiovascular end point (3P-MACE [3-point major adverse cardiovascular event]), as well as secondary end points of hospitalization because of heart failure, cardiovascular morbidity, total mortality, and renal end points.2 We tested the hypothesis that improvements of vascular function and stiffness are involved in the observed improved cardiovascular and renal outcomes with empagliflozin treatment.In this investigator-initiated prospective, double-blind, randomized, placebocontrolled, crossover, interventional single-center trial, 76 female and male patients (18-75 years of age) with diagnosed type 2 diabetes mellitus were randomized to either empagliflozin 25 mg orally once daily or placebo for 6 weeks, followed by the second 6-week treatment with the other compound (crossover).In 64 patients, any antidiabetic agent was withdrawn 4 weeks before the baseline examination.We analyzed the effects of empagliflozin on central hemodynamics and vascular function at baseline (untreated status), after 6 weeks with empafliflozin/placebo, and after another 6 weeks with the other compound.The study protocol was approved by the local ethics committee, and written informed consent was obtained.To measure central systolic pressure and central pulse pressure, radial artery waveforms were recorded by the SphygmoCor System (AtCor Medical), and corresponding central (aortic) waveforms were then automatically generated through a validated transfer function.3 During 24-hour ambulatory, daily-life conditions, brachial blood pressure (BP), and derived central (aortic) pressure curves (obtained through a validated transfer function) were assessed by the Mobilograph (IEM).4 Statistical analysis was performed in the per protocol population (N=71).All patients (59% males, 62±7 years of age) were white, and 10 patients had established cardiovascular disease.At baseline, HbA1c was 6.75±0.8%,body weight 89.2 kg, office BP 129±14/77±7.6mm Hg, and ambulatory BP 129±10/79±7.1 mm Hg.Compared with placebo, empagliflozin effected a decrease of HbA1c (-0.26±0.44%,P=0.001), fasting glucose (-24.9±26mg/dL, P<0.001), body weight (-1.08±1.5 kg, P<0.001), brachial office BP (-5.20±7.8/-1.70±6.1 mm Hg, P<0.001/P=0.021),and 24-hour ambulatory BP (-2.13±7.3/-1.93±5.1 mm Hg, P=0.017/0.002).No safety issues were noted throughout the study.Under office conditions, central systolic (primary objective) and central pulse were lower by 5.14 mm Hg (P<0.001) in the empagliflozin group than in the placebo group after 6 weeks of treatment (Figure).Accordingly, a decreased forward pressure wave amplitude and a reduced reflected pressure wave amplitude were
Source: Circulation
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2755863750
FWCI: 9.276
Cites: 5
Cited by: 178
Related to: 10